Quinazoline derivatives: synthesis and bioactivities by unknown
Wang and Gao Chemistry Central Journal 2013, 7:95
http://journal.chemistrycentral.com/content/7/1/95REVIEW Open AccessQuinazoline derivatives: synthesis
and bioactivities
Dan Wang and Feng Gao*Abstract
Owing to the significant biological activities, quinazoline derivatives have drawn more and more attention in the
synthesis and bioactivities research. This review summarizes the recent advances in the synthesis and biological
activities investigations of quinazoline derivatives. According to the main method the authors adopted in their
research design, those synthetic methods were divided into five main classifications, including Aza-reaction,
Microwave-assisted reaction, Metal-mediated reaction, Ultrasound-promoted reaction and Phase-transfer catalysis
reaction. The biological activities of the synthesized quinazoline derivatives also are discussed.
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Quinazoline derivatives, which belong to the N-containing
heterocyclic compounds, have caused universal concerns
due to their widely and distinct biopharmaceutical activities.
Researchers have already determined many therapeutic
activities of quinazoline derivatives, including anti-cancer
[1-4], anti-inflammation [5,6], anti-bacterial [7-10], anal-
gesia [5,9], anti-virus [11], anti-cytotoxin [12], anti-spasm
[9,13], anti-tuberculosis [14], anti-oxidation [15], anti-
malarial [16], anti-hypertension [17], anti-obesity [18],
anti-psychotic [19], anti-diabetes [20], etc. Medicinal
chemists synthesized a variety of quinazoline compounds
with different biological activities by installing various
active groups to the quinazoline moiety using develop-
ing synthetic methods. And the potential applications of
the quinazoline derivatives in fields of biology, pesti-
cides and medicine have also been explored. This review
summarized the representative synthetic methods, either
traditional or novel, and categorized them into five main
classifications, including Aza-reaction, Microwave-assisted
reaction, Metal-catalyzed reaction, Ultrasound-promoted
reaction and Phase-transfer catalysis. Besides, three other
kinds of reactions were also listed out, which were either
designed as supplementary methods in most experi-
ments or used as the main methods in some researches,* Correspondence: gaofeng@sicau.edu.cn
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One-pot synthesis. In addition, the bioactivity researches
of quinazoline derivatives were also discussed in order to
provide valuable reference for the future synthesis and
biological investigation of these compounds.Review
Synthetic methods
Aza-reaction
Aza-Diels-Alder reaction Imino-Diels-Alder reaction
[21] containing the coupling of imine and electron-rich
alkene gradually became a powerful tool for the synthesis
of quinazoline derivatives [22]. In Povarov imino-Diels-
Alder reaction, aniline and ethyl glyoxalate were chosen
as substrates. And two molecules of α-iminoesters, which
were got from the condensation of aniline and ethyl
glyoxalate, were hypothesized to form the direct additive
product. Cascade Imino-Diels-Alder reaction conducted
by Chen et al. [23] was extended from the Povarov Imino-
Diels-Alder reaction. In this research, researchers chosed
the same substrates as in the Povarov Imino-Diels-Alder
reaction, and adopted various kinds of Lewis acid as cata-
lysts, then the reagents were refluxed in toluene for one
day, and finally produced quinazoline derivatives 3. CuBr2
was determined as the optimized catalyst with highest
yields (Scheme 1).ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
















Scheme 1 Synthesis of derivatives 3 by cascade imino-Diels-Alder reaction.
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http://journal.chemistrycentral.com/content/7/1/95Aza-Wittig reaction Aza-Wittig reaction, which gener-
ally precedes in cascade with easy operation under mild
reaction conditions, is widely used in the synthesis of N-
heterocycles [24]. He et al. reported a kind of tandem
Staudinger–Aza-Wittig–Nucleophilic addition reaction to
synthesize indolo[1,2-c]quinazolines recently [25]. The
main synthetic procedure of this research was using
azides 4 and triphenylphosphine to react in toluene for
2 h at room temperature, and then heating at reflux
for 6–24 h. Results showed that the nitrogen evolution
through the Staudinger reaction halted during the ini-
tial 2 h, and surprisingly produced the final product
indolo[1,2- c]quinazolines 6 directly from the reaction
mixture (Scheme 2).A synthetic method for 2-alkoxy-
3H-quinazolin-4-ones was reported by Ding et al. in
2004 [26]. In this study, twelve novel 2-alkoxy-3H-
quinazolin-4-ones were synthesized from carbodiimide
8, which was obtained from aza-Wittig reaction of
iminophosphorane 7 with aromatic isocynate (Scheme 3).
Sophie Barthelemy et al. applied perfluoroalkyl-tagged





















Scheme 3 Synthesis of 2-alkoxy-3H-quinazolin-4-ones.synthesis of 3H-quinazolin-4-ones by aza-Wittig reaction
[27]. Compounds such as Type 11 were adopted as sub-
strates to react quantitatively with per fluoro-tagged
phosphine 12 to obtain iminophosphoranes 13. Then
these intermediates converted directly into the desired
quinazoline derivatives through intramolecular aza-Wittig
reaction. The reactions were preceded in toluene as
solvent and trifluorotoluene as co-solvent (Scheme 4).
After the reaction, desired products 15 were separated
through solid-extraction on fluorous reversed-phase sil-
ica gel, for that the unreacted iminophosphoranes 13
and phosphane oxide 14 would leave the perfluoro tag
on silica gel, thus make the products be washed off
effectively. In this way, it was made possible for simple
segregation of quinazolin-4-ones even with unquantitative
cyclization reaction.
Microwave-assisted synthesis
Compared to traditional heating methods, microwave
heating could expand reaction range as well as shorten
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Scheme 4 Synthesis of 3H-quinazolin-4-ones via aza-Wittig reaction.
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http://journal.chemistrycentral.com/content/7/1/95minutes. Thus, when applied in fields of organic syn-
thesis, pharmaceutical chemistry and high-throughput
chemistry, microwave heating shows greater advantage
than traditional heating methods [28-31].
Luo et al. reported the first microwave-assisted
synthesis of new quinazoline derivates containing α-
aminophosphonate [32]. In their method, N’-(substituted-
2-cyanophenyl)-N,N-dimethyl-formamidine derivatives and
dialkyl amino (phenyl) were adopted as the raw materials
to react in 4:1 volume ratio of isopropanol to acetic acid
solvent for 20 min under microwave irradiation (100°C,
100 psi), and obtained twenty-four quinazoline compounds
18, two of which had similar activity as commercial reagent
Ningnanmycin (Scheme 5).
Tu et al. reported a fast, one-pot, microwave-assisted syn-
thesis of polysubstituent imidazo[1,2-a]quinoline, pyrimido
[1,2-a]quinoline and quinolino[1,2-a]quinazoline derivatives
[33]. They explored the optimal reagent, volume and
heating temperature by testing different reagents under
different reaction time and temperature. Then under the
optimal conditions (2.0 mL glycol and 120°C),several alde-
hydes were separately reacted with various enaminones






























Scheme 6 Microwave-assisted one-pot synthesis of quinazoline compIn the synthetic research conducted by Kidwai et al.
[34], the target compounds quinazoline derivatives 28
were obtained by heating an equimolar amount of alde-
hyde 25, 5,5-dimethyl-1,3-cyclohexanedione (dimedone)
26 and urea/thiourea 27 under microwave irradiation in
the absence of solvent and catalyst (Scheme 7).
Hazarkhani et al. adopted isatoic anhydride and 2-
aminobenzimi-dazole as the raw materials, DMAC as
solvent in their starting research and got 2-amino-N-(1-H -
benzimidazol-2-yl) benzamide under microwave irradiation
[35]. Then they discovered that this novel amide has three
nucleophilic sites to condense with different electrophilic
compounds, which made it applicable for the synthesis of
numerous quinazolinone based targets, and was applied in
the following synthesis.
Amides (5 mmol), triethylorthoformate (7.5 mmol), p-
tolue-nesulfonic acid (0.25 mmol) and DMAC (1–2 ml)
were mixed in a tall beaker covered with stem-less fun-
nel, and heated for 4 min under 600 w microwave power
in a microwave oven, then interrupted in between with a
cooling procedure. After that, the reaction mixture was
cooled to room temperature and poured into a large vol-

















































Scheme 7 Solvent-catalyst-free microwave-assisted synthesis of quinazolines.
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http://journal.chemistrycentral.com/content/7/1/95filtered and recrystallized with 95% ethanol to obtain pure
product 3-benzimidazolyl-4(3H)-quinazolinone (31) with
a yield of 94% (Scheme 8).
Metal-mediated reaction
Palladium-catalyzed reaction
Palladium-catalyzed coupling reaction, which plays a vital
role in the pharmaceutical industry, is widely applied in
chemical synthesis industry and laboratories as an efficient
method for the formation of C-C and C-heteroatom bond.
Qiu et al. determined the optimum conditions for
the palladium-catalyzed three-component synthesis of
quinazolino[3,2-a]quinazolines as follows: amine (3.0 equiv),
isocyanide (3.0 equiv), carbodiimide (0.2 mmol), Pd(OAc)2
(5 mol%) and Cs2CO3 (3.0 equiv) in 3.0 ml toluene
(Scheme 9) [36].
McGowan et al. developed a palladium-catalyzed one-
pot synthesis of quinazoline derivatives [37]. The reaction
process was shown in Scheme 10.
Zinc-reduced synthesis Zinc is the first capable metal
found to participate in water-phase Barbier reaction. It
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Scheme 9 Synthesis of quinazolino[3,2-a]quinazolines.compounds as well as participate in the benzylation of
carbonyl and some special alkylation. Apart from partici-
pating in the carbon-oxygen double bond Barbier reac-
tion, Zinc could also be applied to carbon-nitrogen double
bond Barbier reaction, such as the allylation of imine and
α-amino aldehyde. In short, Zinc could stably exist in
water phase with relatively strong activity. Active zinc
obtained from ultrasonic-electrical method could even
improve the reaction efficiency by more than three
times. Although it often causes a few side effects, the
cost-effectiveness and low-toxicity of zinc made it a good
catalyst for organic reduction and synthetic reaction. In
the synthetic research of imidazo[1,2-c]quinazoline
derivatives designed by Shi et al. [38], 2-(2-nitro-
phenyl)-1H-imidazoles 39 was reduced by Zn/H+ to 2-
(2-aminop henyl)-1H-imidazoles 40, which then reacted
with isothiocyanates to get intermediate 41. Cylization
of compound 41 by nucleophilic attack of the nitrogen
atoms on C = S group was afford the intermediates 42.
Finally, the desired products 43 were obtained from 42
by losing of H2S (Scheme 11). Low-valent titanium re-
agents, which aroused an increasing concern in the field
































Scheme 10 Palladium-catalyzed one-pot synthesis of quinazolines.
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http://journal.chemistrycentral.com/content/7/1/95coupling of carbonyl compounds [39]. A synthetic
method assisted by low-valent titanium reagent was
reported by the same group mentioned above [40]. In
this synthesis, a series of quinazoline derivatives were
afforded by adopting anhydrous THF as solvent and the

















































Scheme 12 TiCl4-Zn-mediated reduced synthesis of quinazoline derivsynthetic routes were selected, which were shown in
Scheme 12.
Copper-catalyzed reaction Aryl ether, alkyl ether, aryl
amine, alkyl amine, aryl sulfide, alkyl sulfide, etc., which












































X = C, N























Scheme 13 Copper-catalyzed synthesis of indolo[1,2-c]quinazoline derivatives.
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http://journal.chemistrycentral.com/content/7/1/95chemical molecules, have an urgent need for better syn-
thetic methods. Classical copper-catalyzed Ullmann reac-
tion has been widely studied due to its significant role in
this regard. It raised attention from many chemists and
became one of the focal point in organic chemistry re-
search in recent years. Sang et al. reported a copper-
catalyzed sequential Ullmann N-arylation and aerobic
oxidative C-H amination for the convenient synthesis of
indolo[1,2-c]quinazoline derivatives [41]. In their research,
2-(2-halophenyl)-1H-indoles and (aryl)methanamines were
adopted as raw materials to generate corresponding Schiff
base via Ullmann reaction. Then gas as oxidant, 3 equiv
K2CO3 as base, DMSO as solvent and 10 mol% Cu(OAc)2
as catalyst were revealed as the optimum conditions, to
conduct aerobic oxidative C-H amination under 110°C
(Scheme 13).Jiang et al. also reported a copper-catalyzed
one-pot synthesis of 5,12-dihydroindolo[2,1-b]quinazolines
[42]. The best conditions of catalyst, ligand, base and
solvent were determined as 10 mol% of CuI, 20 mol% of
trans-4-hydroxyl-L-proline, 3.0 equiv of K2CO3, DMSO
and 90°C, respectively. N-(2-bromobenzyl)-2-iodoani-line
(57) and malononitrile (58) were adopted as the raw
materials to afford desired compound 59 through copper-
catalyzed intramolecular C-N coupling reaction (Scheme 14).
A two-step catalytic synthesis of 2-substituted-1,2,3,4-
tetrahydroquinazolinones was investigated by Kundu et al.
[43], including the palladium-copper co-catalyzed
C-arylation of terminal alkynes and copper-catalyzed
cyclization of disubstituted alkynes. First of all,
2-(N-Alkyl-N-prop-2′-ynyl)amino-N’-p-tosyl benzamides
and aryl iodides were adopted as the raw materials to react
in presence of 5 equiv of Et3N for 16 h, catalyzed by
2.5 mol% (Ph3P)2PhCl2 and 5 mol% CuI, to generate a
series of disubstituted alkynes. Then the products were
cyclized in the presence of CuI (30 mol%), K2CO3 (2.5
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Scheme 14 Copper-catalyzed one-pot synthesis of quinazolines derivto afford the desired products 1-methyl(benzyl)-(E)-2-
(2-arylvinyl)-3-p-tosyl-1,2,3,4-tetrahydroquinazoline-4-ones
with high yield. The structures of obtained compounds
were shown in Figure 1.
Ultrasound-promoted synthesis
In critical synthesis, ultrasonic assistance is needed to
meet the high requirements for temperature and pressure.
For instance, in Bischler cyclization [44-46], the most
traditional synthetic methods for quinazoline derivatives,
high temperature (above 120°C) and high pressure are
needed for at least 5 h in saturated ammonia alcohol so-
lution. Various synthesis applying this method contains
the passage of ammonia through a mixed melt of the
amino compound and sodium acetate at a temperature
higher than 160°C [47], in which ultrasonic promotion
is demanded.
Zhang et al. reported an ultrasound-assisted synthesis
of novel quinazoline derivatives, including a four-step
synthesis of quinazoline core and the optimization of the
Bischler cyclization [48]. The optimum reagents and
conditions of the four steps were as follows: (a) iron
powder(reductant), concentrated HCl(catalyst), ethanol/
water(co-solvents with V:V of 5:1), 50°C; (b) 4-nitrobenzoic
acid chloride(1 equiv), TEA(1.2 equiv), DCM, 0°C; (c) 25%
ammonia water, water, ultrasound 250 W, 80°C, 3 h; (d)
iron powder, concentrated HCl, ethanol/water, 50°C
(Scheme 15).
Phase-transfer catalysis
Phase-transfer catalysis (PTC) is considered to be one of
the promising methods in organic synthesis of specialty
chemicals. The previous 20 years sees a steady incre-
ment in articles and patents dealing with PTC topics
and their applications. Currently, rather than be simply















Figure 1 Structures of palladium-copper co-catalyzed synthesis
of quinazolines.
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http://journal.chemistrycentral.com/content/7/1/95polymer chemistry, heterocyclic chemistry, organometal-
lic synthesis, agrochemicals, dyes, flavors, spices, and
pharmaceutical technology [49-51].
In the synthetic research conducted by A. Kh. Khalil
[52], the optimum conditions were determined as fol-
lows: Dioxane/anhydrous potasstium carbonate be set
as liquid/solid phases and TBAB be set as catalyst. The
2-mercaptoquinazolin-4(3H)-one (65) was stirred effect-
ively with haloorganic reagents under optimal condi-
tions at 25°C for 2-4 h. Then in the following tests,
compound 65 was treated respectively with ethyl bromide,
allyl bromide, bromoactylacetone, and diethyl malonate
bromide by molar ratio of 1:3, and afforded a series
of quinazoline derivatives via S-monoalkylation. While
treatments with several other compounds, including methyl
iodide, benzyl bromide, ω-bromo-4-methoxyacetophenone,
ethyl bromoacetate, and chloroacetyl chloride could afford
products 66 via a simultaneous S- and N-dialkylation
(Scheme 16).
Yao et al. designed an investigation to bring bromine
into the active structure of quinazoline sulfide [53].














Scheme 15 Ultrasound-assisted four-step synthesis of novel quinazolgenerate a series of 6-bromo-4-alkylthioquinazoline com-
pounds 74 via phase-transfer catalysis through a sequence
of reaction, including acylation, bromination, hydrolysis,
ring formation, vulcanization and thioether substitution
(Scheme 17).
Apart from the five synthetic methods listed above,
several other methods could also be used as main
researching methods in some situation, while most of
the time, they were set as auxiliary methods or necessary
methods in experimental design. Here, several examples
of such methods were listed.
Oxidative cyclization
A three-step synthesis of mono- and bis-indolo[1,2-c]
quinazolines was reported by Rohini et al. in 2010 [7].
In this research, the key indole precursor A was got
from Fischer indole cyclization. And the corresponding
intermediate mono and bis-2-(o-arylidineaminophenyl)
indole, obtained from indole precursor A, then was put
on oxidative cyclization with powdered KMnO4 in acet-
one to afford the desired products mono and bis-indolo
[1,2-c]quinazoline.
In 2009, they also reported another synthesis of mono-




Chandrika et al. synthesized desired products from the
intermediate obtained from reagent refluxing [12]. In
the synthesis of tri-substituted products triazolo[4,3-a]-
quinazolin-7-ones by Pandey et al. [55], the corre-
sponding Schiff base was obtained from refluxing of
key intermediate with isatin in methanol, which then
cyclodehydrated to the products in concentrated sul-
furic acid. Aside from these two researches, in some
other synthetic researches [5,34,56], the intermediates
or products were also obtained from refluxing of raw
materials or intermediates in solvent.
One-pot synthesis
In order to make the synthetic methods more convenient,
many researchers gradually tend to integrate one-pot



























Scheme 16 PTC synthesis of alkylation quinazoline derivatives.
Wang and Gao Chemistry Central Journal 2013, 7:95 Page 8 of 15
http://journal.chemistrycentral.com/content/7/1/95microwave-assisted synthesis reported by Tu et al. [33],
Copper-catalyzed domino synthesis reported by Jiang et al.
[42], Palladium-catalyzed reaction reported by McGowan
et al. [37] and Zinc-reduced synthesis reported by Shi
et al. [38]. All of these reported methods were combined
with one-pot synthesis.
Bioactivity research
4-position substituted quinazoline compounds
Melanin-concentrating hormone receptor 1 antagonists
MCHR1 antagonising quinazoline derivatives are proved
to possess distinct anti-obesity activity. Sasmal et al. in-
vestigated the potential anti-obesity activity of quinazoline
derivatives, which were determined as MCHR1 antagonists
[18]. A series of compounds were obtained by the change
of substituent groups, including 4-propyl-quinazolinone, 4-
pyrrolidin-quinazolinone, 4-hydroxypiperidine-quinazoline,
4-pyrrolidin-quinazoline, 4-morpholinyl-quinazoline, etc.
Firstly, the metabolic stability in blood and solubility of
these compounds were studied. Then, their anti-obesity
properties were tested. 4-Morpholinyl-quinazoline (75,
Figure 2) showed good oral PK profile and was chosen as
a prototype molecule used to test its effect in DIO
C57BL/6 J mice. And the tested mice reached an obvious
weight reduction of 12% in the fourteenth day, by oral
administration of that compound (30 mg/kg, b.i.d.). The re-
sults showed, the representative compound 4-morpholinyl-
quinazoline owned an obvious anti-obesity activity.
However, it was also pointed out that the compound was in
need of further improvement of stability in plasma related
to the oxymethylene linker.Besides, there are a number of





















Scheme 17 PTC synthesis of 4-alkylthio-quinazoline derivatives.inhibitory activity for MCHR1, including 4-amino-2-cyclo-
hexyl aminoquinazoline, 4-dimethylamino quinazoline,
etc. Among these compounds, which work as MCHR1
antagonists, some N-substituted amino quinazoline
compounds exhibit high IC50 values due to their good
affinity for human MCHR1, including ATC0065 and
ATC0175 [57-59].
Epidermal growth factor receptor tyrosine kinase inhibitors
Researches suggest that EGFR tyrosine kinase inhibiting
quinazoline derivatives possess significant anti-cancer
activity. 4-Anilinoquinazoline showed a potent and
highly selective inhibition for EGFR tyrosine kinase
through ATP-competitive binding mechanism [60-66].
And quinazoline derivatives with aliphatic branch at 4-
position of quinazoline core have moderate inhibitory
activity for cyclin-dependent kinase [67].
Chandregowda et al. synthesized novel 4-anilinoquinazolines
and evaluated their anti-cancer activity [1]. The new re-
sults indicated that quinazoline derivatives with alkyl-
thiobenzothiazole side chain in 6-position and electron
withdrawing group substituted in 4-aniline contain bet-
ter biological activities.
Lately, synthesis and activity research on 4-
anilinoquinazolines as well as extended researches on
inhibitory activity of anilinoquinazolines for EGFR are
reported continuously [68].For example, Hu et al.
designed and synthesized several crown ether fused
anilinoquinazoline analogues, combined with EGFR
kinase in vitro test and EGFR mediated intracellular
phosphorylation test [69]. IC50 values of these com-
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Figure 2 Structures of representative 4-substituted quinazolines with bioactivity.
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http://journal.chemistrycentral.com/content/7/1/95indicated that substituent of ethynyl at meta-position
or halogen on the 7-anilino were desirable for high po-
tency. And among the products, compound 76 (Figure 2)
expressed high resistance for EGFR and potent selectivity
for kinases Abl and Arg, and showed good pharmacoki-
netic properties in preclinical evaluation. Moreover, it
inhibited the growth of many human solid tumor xeno-
grafts in a dose-dependent way(range 50–100 mg/kg).
Acrolein amine quinazolines substituted on the 6-
position could irreversibly bind with intracellular ATP
binding domain of EGFR [70,71]. 6-Substituted-4-anilino
quinazolines with irreversible binding property with EGFR
were synthesized by Vasdev et al., starting from [18 F]
fluoroanilines [3].
There are some other researches aiming at replacing
4-anilino with other substituents [72-74], such as
thiosemicarbazide, which possesses a variety of biological
profiles, including anti-cancer, anti-fungi, anti-bacterial,
anti-inflammation and anti-virus. Thus it acts as an effi-
cient pharmacophore in drug design. In order to find
novel quinazoline compounds with same enzyme sites
as 4-anilinoquinazoline, a series of 4-thiosemicarbazide
quinazolines were synthesized by He et al.[75], and their
anti-cancer activities were estimated using 5 human
cancer cell lines with 5-FU as reference. Preliminary
results showed that some produced compounds exhibited
better inhibitory activity against these 5 human cancer
cell lines than 5-FU. Structure-activity relationship re-
sults indicated that compounds with unsubstituted
quinazoline ring and benzene ring or chloro/fluoro
substituted benzene ring were proved to have higher
anti-cancer activity.Platelet-derived growth factor receptor phosphorylation
inhibitors
Cell proliferation induced by unusual platelet-derived
growth factor receptor (PDGFR) will lead to a variety of
proliferative diseases such as atherosclerosis, restenosis
following PTCA, glomerulonephritis, glomerulosclerosis,
liver cirrhosis, pulmonary fibrosis, and cancer [76-86].
PDGFR phosphorylation inhibitors are potential treat-
ments for these proliferative diseases [87].
Matsuno et al. obtained a series of compounds
containing 4-piperazinyl substituted quinazoline core
from screening of PDGFR phosphorylation inhibitors
[87]. KN1022 was adopted as the prototype inhibitor
in structure-activity relationship analysis, and the 4-
nitrobenzene urea moiety was studied, which indicated
that compounds with substitution on 4-position of
benzene ring worked best, but activity would be re-
duced with more than two substituents on benzene
ring. In their research, several KN1022 (77) (Figure 2)
derivatives with favorable activity were obtained, including
4-(4-methylphenoxy)phenyl,4-tert-butylphenyl and 4-
phenoxyphenyl. In vivo assays were conducted by oral
administration of these three compounds (30 mg/kg, twice
daily) to SD rats. 4-chlorophenyl (78), 4-bromophenyl
(79), and 4-isopropoxyphenyl (80) (Figure 2) analogues
were then proved to have obvious inhibitory activity
against neointima formation in the carotid artery of the
balloon catheter de-endothelialized vessel in the rats.
Germicide
Li et al. synthesized and biologically evaluated a series
of 4-quinazoline oxime ether compounds in purpose of
Wang and Gao Chemistry Central Journal 2013, 7:95 Page 10 of 15
http://journal.chemistrycentral.com/content/7/1/95discovering novel acaricides [11]. Compounds obtained
in this research were proved to have different degrees of
suppression for phytovirus TMV, among which com-
pound 81 (Figure 2) showed potent in vivo and in vitro
activity against TMV, 65% and 61% respectively. What’s
more, bioassays showed that compound 81 also exhibited
favorable inhibitory activities against CMV,PVX and PVY
after virus vaccination.Heterocyclic quinazoline derivatives
Imidazo-quinazolines In the synthesis of mono and
bis-6-arylbenzimidazo[1,2-c]quinazolines by Rohini et al.
[54], bioassays were conducted applying standard drugs
Ampicillin and Ketoconazole as references. Among the
products, the MIC of compound 82 (Figure 3) against
Staphylococcus aureus, bacillus subtilis, streptococcus
pneumoniae, Salmonella typhimurium, escherichia coli,
klebsiella pneumoniae, aspergillus niger, candida albicans
and Trichoderma viridae were 2.5, 10, 5, 5, 2.5, 5, 2.5,
2.5, 5 μg/mL respectively.Rewcastle et al. synthesized
several fused tricyclic quinazoline analogues and inves-
tigated their enzyme inhibitory activity [88]. Linear
imidazo[4,5-g]quinazoline (83) was proved to be the most
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Figure 3 Structures of representative heterocyclic quinazoline derivatand the N-methyl analog (84) showed similar activity
as compound 83 (Figure 3). In the imidazo[4,5-g]
quinazoline and pyrroloquinazoline series, the angular
isomers showed much weaker inhibitory ability than
the linear compounds, which was consistent with the
results of the previous structure-activity relationship.
Meanwhile, small electron-donating substituent at the
6- or (and) 7-positions was beneficial to the inhibitory
activity.Acylhydrazone quinazolines Acylhydrazone is a
pharmacophore armed with favorable activity of anti-
biosis, anticancer and antivirus. Panneerselvam et al.
synthesized several acylhydrazone quinazolines via con-
densation reaction of 3-amino-6, 8-dibromo-2-phenyl-
quinazolin-4(3H)-ones and aromatic aldehyde [13]. Among
which, the representative compound 85 (Figure 3) showed
the most significant activity against S. aureus, S. epidermidi,
M. luteus, B. cereus, E. coli, P. aeruginosa, K. pneumoniae,
A. niger and A. fumigatus.Triazole quinazolines Triazole quinazolines aroused
attention for their various bioactivities. Baba et al.
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http://journal.chemistrycentral.com/content/7/1/95derivatives [6]. Justicidins, the potent bone resorption
inhibitors, were adopted as lead compounds, and
quinazoline derivative 86 was discovered to show favor-
able anti-inflammatory effect on rats with adjuvant arth-
ritis. Then the structure of compound 86 was modified by
adding heteroaryl moiety on the alkyl side chain at 2-
position of the skeleton, result of which showed that
installation of an imidazole or a triazole moiety on the
2-alkyl side chain could increase the anti-inflammatory.
Then, compound 86 with ED50 of 2.6 mg/kg/day was
selected as candidate for further research, which showed
that the inhibitory ability against Th1 cytokine production
of 87 was considered to be its significant immune regu-
lating function (Figure 3).Fifteen [1,2,4] triazole [4,3-c]
quinazoline derivates were synthesized and evaluated
for their antimicrobial activity by Jantova et al. [89],
among which, compound 88 (Figure 3) was found with
the highest potency against Bacillus subtilis, Staphylococ-
cus aureus, Candida tropicalis and Rick-ettsia nigricans.
Nasr et al. evaluated the antimicrobial activity of novel
1,2,4-triazolo[4,3-c]-quinazoline analogues against typical
gram-positive bacterium and Gram-negative bacterium
[90]. Among these analogues, tetracyclic compound 89
showed higher activity than the reference drug of cipro-
floxacin (Figure 3).Besides, 2-thio-[1,2,4]triazolo[1,5-c]
quinazolinones with C-5 substituted by sulfo-alkyl
groups were discovered with moderate antimicrobial
activity [91-93]. Based on the former researches,
Antipenko et al. synthesized novel 2-thio-[1,2,4]triazolo
[1,5-c]quinazoline derivatives and investigated their bioac-
tivities [8]. Escherichia coli, Pseudomonas aeruginosa, As-
pergillus niger, Mycobacterium luteum, Candida albicans
and Candida tenuis were applied in the antimicrobial
test, which showed that compounds 90 and 91 exhibited
obvious suppression for Candida albicans, which was
validated by further bioluminescence inhibition test







95 R1 = CH3, R2 = CH2CH3
96 R1 = CH2CH3, R2 = CH2C
97 R1 = CH3, R2 = CH2CH2C
Figure 4 Structures of representative other quinazoline analogues.also conducted antimicrobial researches on novel
quinazolinones fused with [1,2,4]-triazole, [1,2,4]-triazine
and [1,2,4,5]-tetrazine rings [55]. Among the quinazolinones
derivates, compounds 92, 93 and 94 (Figure 3) showed ex-
cellent activities against Escherichia coli, pseudomonas
aeruginosa, streptococcus pneumoniae, and bacillus subtilis.
Other quinazoline analogues
2,3-Disubstituted quinazolines 2,3-Disubstituted quina-
zolin-4(3H)-ones have been discovered with favorable
analgesic and anti-inflammatory function [94,95]. Alagarsamy
et al. reported several 2,3-disubstituted quinazoline analogues
with potent analgesic and anti-inflammatory activity, such
as 2-phenyl-3-substituted quinazolines [96], 2-methyl-
3-substituted quinazolines [97], 2-methylthio-3-substituted
quinazolines [98] and 2,3-disubstituted quinazolines [99]. On
the basis of these researches, they synthesized novel 3-phenyl
-2-substituted-3H-quinazoline-4-ones in purpose of further
reducing the ulceration side effects [5]. And the analgesic,
anti-inflammatory and ulcerogenic index activities of these
compounds were tested. Among the synthesized derivates,
compounds 95, 96 and 97 (Figure 4) showed moderate
analgesic activity. It is worth to mention that compound
97 exhibited higher anti-inflammatory potency, refer-
ence to standard drug of diclofenac sodium. In addition,
the evaluated compounds all caused milder ulceration
side effects, reference to aspirin.Indole-involved quinazolines Indole moiety involved
heterocycles are proved to have a wide variety of pharma-
ceutical and medical profiles, such as anti-inflammation,
anti-microbial, anti-cancer, anti-malarial, etc. [100-106].
Rohini et al. conducted anti-microbial study on the newly
produced 6-substituted indolo[1,2-c] quinazolines apply-
ing gram-positive bacterium (Staphylococcus aureus,
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http://journal.chemistrycentral.com/content/7/1/95bacterium (Salmonella typhimurium, Escherichia coli and
Klebsiella pneumonia), and pathogenic fungus (Aspergillus
niger, Candida albicans and Trichoderma viridae) as the
test bacterium, and standard drug ampicillin and ketoco-
nazole as reference, which indicated that some of the syn-
thesized compounds showed favorable inhibition against
the tested microorganism [7].
2,4,6-trisubstituted quinazolines Chandrika et al. syn-
thesized and biologically evaluated various 2,4,6-trisubstituted
quinazoline derivatives. The core of compound 98 (Figure 4)
showed antimicrobial activities against gram-positive bac-
terium and gram-negative bacterium. In addition, it could
be drawn from the SAR that decylamine group substituted
at C-4 is beneficial to the activity while iodo-group at C-6
is detrimental to activity [12].
Conclusions
Traditional synthetic methods for quinazoline derivatives,
still in general use, including Aza-synthetic method,
refluxing, oxidative cyclization, are fundamental methods
for the synthesis of this important heterocyclic com-
pounds. It could be seen from the examples compiled
above that some novel synthetic methods are in constant
development, and different methods are adopted in the
synthesis of different quinazoline analogues, such as
phase-transfer synthesis, ultrasound-promoted synthe-
sis, etc. The gradually improved synthetic methods bet-
ter the synthetic research on quinazoline derivatives
with a tendency of faster, more diverse and more con-
venient. Then, for another, it is known that substituents
at different positions affect the activity differently. For
instance, quinazoline derivatives with imidazole substituted
at the 2-position of side chain own potent anti-
inflammatory function; and quinazoline derivatives with
amine or substituted amine on 4-position and either
halogens or electron rich substituent groups on 6-
position could promote the anti-cancer and anti-
microbial activities [7,12], etc. By careful observation of
the recent researches, 2-, 4- and 6-position substituted
quinazoline analogs remain majority among the prod-
ucts. However, with the deepening and development of
researches, substituent groups at other positions are
also achieved and studied increasingly, such as the con-
struction of N-heterocyclic quinazolines by introduction
of active groups into 3-position of quinazoline core. It is
worth mentioning that N-heterocyclic quinazolines
with more rigid and complicated structure were syn-
thesized successively, some of which showed excellent
antimicrobial properties. In addition, it could be drawn
from the research progress above that enhancement of
activity by splicing method of installing various active
groups is and will still be the main method for drug
design and reconstruction of quinazoline derivatives.Competing interests
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